Adage Capital Partners GP L.L.C. Invests $992,000 in Liquidia Co. (NASDAQ:LQDA)

Adage Capital Partners GP L.L.C. purchased a new position in shares of Liquidia Co. (NASDAQ:LQDA - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 84,376 shares of the company's stock, valued at approximately $992,000. Adage Capital Partners GP L.L.C. owned 0.10% of Liquidia as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of LQDA. Steward Partners Investment Advisory LLC bought a new stake in Liquidia during the 4th quarter worth approximately $59,000. Summit Investment Advisors Inc. boosted its position in shares of Liquidia by 35.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company's stock worth $78,000 after purchasing an additional 1,719 shares during the last quarter. EntryPoint Capital LLC acquired a new position in shares of Liquidia during the 4th quarter worth about $154,000. KLP Kapitalforvaltning AS bought a new stake in Liquidia in the fourth quarter valued at approximately $169,000. Finally, Arizona State Retirement System increased its position in shares of Liquidia by 20.3% in the 4th quarter. Arizona State Retirement System now owns 15,888 shares of the company's stock valued at $187,000 after buying an additional 2,685 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company's stock.

Liquidia Stock Up 13.2 %

Shares of Liquidia stock traded up $1.85 during trading on Friday, reaching $15.83. The company's stock had a trading volume of 3,981,786 shares, compared to its average volume of 988,231. The business's 50-day moving average price is $14.22 and its 200-day moving average price is $13.00. Liquidia Co. has a 52 week low of $8.26 and a 52 week high of $16.81. The firm has a market cap of $1.35 billion, a PE ratio of -9.71 and a beta of 0.23.

Liquidia (NASDAQ:LQDA - Get Free Report) last announced its earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.08). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The business had revenue of $2.92 million for the quarter, compared to analyst estimates of $4.60 million. Equities analysts predict that Liquidia Co. will post -1.51 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on LQDA. Needham & Company LLC restated a "buy" rating and set a $25.00 target price on shares of Liquidia in a report on Thursday, April 10th. Scotiabank reissued an "outperform" rating on shares of Liquidia in a research report on Thursday, March 20th. Finally, HC Wainwright restated a "buy" rating and set a $29.00 price objective on shares of Liquidia in a research note on Thursday, March 20th. One analyst has rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, Liquidia presently has an average rating of "Buy" and an average target price of $26.63.

Insiders Place Their Bets

In related news, insider Jason Adair sold 1,856 shares of the firm's stock in a transaction on Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $25,185.92. Following the transaction, the insider now owns 184,304 shares in the company, valued at approximately $2,501,005.28. This trade represents a 1.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Rajeev Saggar sold 2,450 shares of the business's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $13.67, for a total value of $33,491.50. Following the completion of the transaction, the insider now directly owns 263,152 shares of the company's stock, valued at approximately $3,597,287.84. This trade represents a 0.92 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 33,138 shares of company stock worth $450,233 in the last 90 days. Company insiders own 30.10% of the company's stock.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).